Point: The Need for Additional FDA Regulations in Laboratory Medicine
The Journal of Applied Laboratory Medicine · 2024
DOI: 10.1093/jalm/jfad084 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Applied Laboratory Medicine, 2024. Verfasst von Eric Q Konnick. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, United States. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Clinical Laboratory Techniques, Government Regulation. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
Laboratory medicine has evolved tremendously in the last few decades. With the advancement of technologies and expansion of medical knowledge, the testing methodologies used in clinical laboratories have become more automated and generate more data with higher throughput capabilities. Over that time, we have also observed a massive consolidation of the laboratory testing industry, with the rise of specialized companies that perform a limited menu of tests on a national or international scale (1). Testing methods have also become increasingly complicated, with single tests, such as genomic or proteomic assays, capable of testing for hundreds or thousands of analytes at a time. Although administrative changes were implemented in 1997 and 2012 amendments, and other focused updates are regularly introduced, substantive updates to the CLIA of 1988 related to regulations on modern technologies have not been enacted (2). The current regulatory system requires laboratories who are providing clinical results to abide by the regulations set forth in CLIA, and manufacturers who produce, sell, and distribute tests are regulated by the US FDA under the Medical Device Amendments passed into law in 1976 (2). Manufactured tests (in vitro diagnostics—IVDs) that are modified or tests that are developed, validated, and performed in a single laboratory are considered laboratory developed tests (LDTs), and are required to have specific performance characteristics assessed under CLIA, but are not currently regulated by the FDA (3). With the modern methodologies that are currently utilized in laboratory medicine and the increasing use of laboratory data to help manage patient care, the FDA and some stakeholders have repeatedly stated that unifying the regulations of LDTs and IVDs may help protect the public from possible failures of these devices and ensure that all tests abide by the same requirements regarding analytical validity, clinical validity, and adherence to manufacturer quality standards. Although controversy exists as to most appropriate way to regulate LDTs, understanding the perspective and viewpoint of the FDA is critical to productive engagement with the agency. Currently, LDTs are regulated by Center for Medicaid and Medicare Services (CMS) through the CLIA regulations. Under CLIA, laboratory personnel and processes are regulated, laboratories undergo inspections every 2 years, and LDTs are potentially assessed for analytic validity (accuracy of the detecting an analyte) but assessment of clinical validity (accuracy of identifying, measuring, or predicting a clinical condition related to an analyte) is not required in statute or regulation. During inspections under current regulations, all or part of aspects of clinical testing components may be examined for compliance. However, the validations of individual LDTs are not required to all undergo assessment, and even when examined during a biennial CLIA inspection, may not be examined in detail. The addition of FDA regulation of LDT design and validation could provide a uniform regulatory requirement for both IVDs and LDTs. Under current regulations, these tests are handled differently, with IVDs generally requiring FDA review under the premarket approval or 510k pathways, while LDTs generally do not have this external performance assessment prior to marketing. Thus, the current regulatory burden for LDTs is different from that for IVDs, possibly leading to lower barriers to market entry and a lack of external assurance of accuracy prior to market introduction for patient testing, potentially leading to safety concerns. The lack of a premarket review of LDT performance may result in incorrect results being provided to patients (4)—although the actual impact of the use of LDTs on patient safety is unknown, as there are currently no requirements that LDT errors be reported to the FDA, even if there are other mechanisms for reporting errors to relevant entities. During the COVID-19 pandemic, the declaration of a public health emergency empowered the FDA to require the analytical validations of SARS-CoV-2 diagnostic tests to be submitted to the FDA as part of the emergency use authorization process, enabling insight into the FDA’s assessment of these tests. In an opinion piece, FDA leadership claimed that analysis of the submitted validations for 125 SARS-CoV-2 LDTs demonstrated 82 with “design or validation problems” (5), although the scope and severity of the deficiencies were not explicitly stated. A separate perspective piece by the same authors stated that manufactured serology tests might also have performance issues or made claims that were not supported by data “the market was flooded with serology tests, some of which performed poorly and many of which were marketed in a manner that conflicted with FDA policy” (6). These opinion pieces have been used by the FDA and others as supportive for increased regulation of laboratory tests, although the specific details of LDT deficiencies have not been publicly released to date. A common concern raised by FDA and some other stakeholders is that LDTs, other than those evaluated as part of the New York State Clinical Laboratory Evaluation Program, have not gone through an external review of the analytical and clinical validity prior to use. As such, some stakeholders claim that it is unknown how the results of such LDTs compare against other methods before introduction and if the results can be reliably used for patient care. A recent example where FDA claimed potential flaws in LDT performance was noninvasive prenatal screening (NIPS) tests, which are used to detect potential fetal chromosomal abnormalities in pregnant individuals. In January of 2022, a New York Times article highlighted several patient stories where false-positive results of NIPS for microdeletion syndromes caused unnecessary distress and worries to expectant families (7). The FDA later issued a news release and safety warning, making patients and health care providers aware that the performance claims of the NIPS testing had not been evaluated by FDA (8). The FDA claims that premarket review of NIPS LDTs may have provided an independent assessment of the clinical and analytical validations of these assays, and may have affected the advertised performance claims that were at center of the published stories or would have required specific information to be communicated to physicians and patients using these tests. Such measures could potentially minimize stress or mitigate harm to patients caused by actual or perceived the deficiencies of LDTs or the performance claims made by companies marketing them. Although there are long-standing post-market programs in place, such as proficiency testing, that are available to compare assay performance between laboratories, some stakeholders note that these programs generally evaluate tests only after they have been used to produce patient results and are only applicable to tests that are comparable across multiple laboratories. Some professional societies and other organizations have stated that the regulation of LDTs and laboratory operations should remain under CLIA and CMS (9, 10). The FDA and others criticize such positions as failing to account for the lack of expertise, personnel, and resources that CMS possesses to administer more intense oversight as part of overseeing LDTs using the CLIA regulations. While the FDA also does not currently possess the resources for oversight of all LDTs, it can collect user fees from medical device manufacturers to supplement the financial requirements of regulating the medical device industry, and thus may be able to scale the infrastructure to regulate LDTs (11). Expansion of such user-fee programs may allow the FDA to extend their activities and hire staff with the appropriate experience. Additionally, the inclusion of multiple exemptions in proposed legislation (12), a technology certification pathway, and allowance for using third-party reviewers for non-high-risk tests could ease the regulatory burden and enhance access to patients. Proponents of FDA oversight have also speculated that regulation of assay development and validation and laboratory operations by separate agencies could result in efficiencies at the level of regulatory agencies. Proponents of FDA regulation of LDTs claim that it could potentially promote innovation and private capital investment in laboratory testing. The claim that application of a uniform regulatory approach could ensure that companies that invest in new laboratory approaches would not be undercut by LDTs that do not have the same requirements as manufactured products. This may reassure investors who are interested in supporting diagnostic innovation that the products and services that are being developed will be assessed for analytical and clinical validity. While many academic institutions publish in the scientific literature regarding the performance data of their LDTs, corporations that are developing potentially innovative approaches may not (13), limiting access to important technical details of specific assays. Proponents cite the rise and fall of Theranos as evidence that investors who contribute private capital, who are not well versed on laboratory testing or the clinical implications of the proposed services, can be susceptible to fraud (14–16). Some stakeholders claim that FDA regulation of laboratory testing could reduce the risk of a similar fraud to future investors by requiring review of all tests before being used clinically, thus providing assurances to investors. Laboratory testing is a critical service to the United States healthcare system and influences a large number of the decisions that are made in patient management. Changes in the current regulatory structure may help mitigate potential harms from existing and future tests, provide a balance of regulatory treatment for all types of tests, enable investment, and protect innovation. A legislative solution, such as the VALID Act, could potentially provide the requisite agencies a flexible approach to regulation, however, the FDA has recently signaled that it will pursue regulation using Notice and Comment Rulemaking through the Medical Device regulations, which may also pertain to laboratory testing (https://www.reginfo.gov/public/do/eAgendaViewRule?pubId=202304&RIN=0910-AI85). If any alternative regulatory proposals are proffered, they will need to address the items that have been raised by regulators and other interested parties with a legitimate intent to address any actual or perceived issues with the full spectrum of laboratory tests and testing services. Author Contributions:The corresponding author takes full responsibility that all authors on this publication have met the following required criteria of eligibility for authorship: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; (c) final approval of the published article; and (d) agreement to be accountable for all aspects of the article thus ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved. Nobody who qualifies for authorship has been omitted from the list. Eric Konnick (Conceptualization-Equal, Supervision-Equal, Writing—original draft-Equal, Writing—review & editing-Equal) Authors’ Disclosures or Potential Conflicts of Interest:Upon manuscript submission, all authors completed the author disclosure form. Research Funding: None declared. Disclosures: E.Q. Konnick has received honoraria from Medscape, Resolution Biosciences, AstraZeneca, Caris, and Roche Diagnostics, and has multiple roles in several professional organizations, including The Association for Molecular Pathology (Chair—Professional Relations Committee, Member—Board of Directors), College of American Pathologists (Chair—Genomic Medicine Committee), and Washington State Society of Pathologists (President).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, United States.
ORCID-Profile: Eric Q Konnick
Zitieren
APA
Konnick, E. Q. (2024). Point: The Need for Additional FDA Regulations in Laboratory Medicine. The Journal of Applied Laboratory Medicine. https://doi.org/10.1093/jalm/jfad084
Vancouver
Konnick EQ. Point: The Need for Additional FDA Regulations in Laboratory Medicine. The Journal of Applied Laboratory Medicine. 2024. doi:10.1093/jalm/jfad084
BibTeX
@article{Konnick2024,
author = {Konnick, Eric Q},
title = {Point: The Need for Additional FDA Regulations in Laboratory Medicine},
journal = {The Journal of Applied Laboratory Medicine},
year = {2024},
doi = {10.1093/jalm/jfad084}
}
EUVIMED